Zenapax

Active Ingredient(s): Daclizumab
FDA Approved: * December 10, 1997
Pharm Company: * HOFFMAN-LA ROCHE
Category: Immunosuppressive

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Zenapax Overview

Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells. In March 2018, it was voluntarily withdrawn from the market by Biogen and Abbvie after reports of autoimmune encephalitis in Europe.[2][3][1] Contents 1 Medical uses 1.1 Discontinued use...

Read more Zenapax Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Daclizumab

Recent Zenapax Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Other drugs which contain Daclizumab or a similar ingredient: (2 results)

• DACLIZUMAB
• ZINBRYTA Daclizumab1 discussion